Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:class |
gptkb:pharmaceuticals
erythropoiesis-stimulating agent |
| gptkbp:clinical_trial |
Phase 3
NCT02631070 NCT03482547 NCT03482560 NCT03682536 NCT03745716 |
| gptkbp:clinical_use |
anemia due to cancer treatment
anemia due to chronic kidney disease |
| gptkbp:compatibility |
do not mix with other drugs
|
| gptkbp:contraindication |
hypersensitivity to luspatercept
|
| gptkbp:dosage_form |
injection
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Reblozyl
|
| gptkbp:indication |
gptkb:myelodysplastic_syndromes
gptkb:anemia |
| gptkbp:ingredients |
luspatercept
|
| gptkbp:invention |
patented
|
| gptkbp:lifespan |
approximately 3 days
|
| gptkbp:manufacturer |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:marketed_as |
gptkb:Reblozyl
|
| gptkbp:patient_education |
injection technique
signs of allergic reaction monitoring blood pressure importance of follow-up appointments dietary considerations during treatment |
| gptkbp:pharmacokinetics |
subcutaneous absorption
modulates TGF-beta superfamily signaling |
| gptkbp:project |
marketed
|
| gptkbp:recommissioned |
with sterile water for injection
|
| gptkbp:research_areas |
hematology
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:safety_measures |
post-marketing surveillance
|
| gptkbp:service_frequency |
once every 3 weeks
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea hypertension allergic reactions diarrhea thromboembolic events injection site reactions increased blood pressure |
| gptkbp:storage |
refrigerated
|
| gptkbp:structure |
gptkb:protein
|
| gptkbp:target_audience |
patients with anemia
|
| gptkbp:trade |
luspatercept-aamt
|
| gptkbp:used_for |
treatment of anemia
|
| gptkbp:bfsParent |
gptkb:Acceleron_Pharma
|
| gptkbp:bfsLayer |
5
|